Imunon narrowed operating and net losses in FY2025 through disciplined cost management including lower employee and consulting expenses, but EPS deteriorated sharply and cash burn persists amid clinical development demands and liquidity constraints.
52W $2.71 – $37.65
Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Beneficial Ownership
Large shareholder position disclosure
Ownership threshold, passive vs active
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
Current Report
Material event disclosure
Event materiality and market reaction
Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction
Current Report
Material event disclosure
Event materiality and market reaction